Compare Estee Lauder Companies Inc (EL) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Estee Lauder Companies Inc vs Zimmer Biomet Holdings Inc — how do they compare? Estee Lauder Companies Inc trades at $88.56 (market cap $31.76B), while Zimmer Biomet Holdings Inc trades at $95.85 (market cap $18.55B). The key difference: Estee Lauder Companies Inc is the larger of the two by market cap, and Estee Lauder Companies Inc pays the higher dividend (1.59%). Which is the better fit depends on your goals.
| EL | ZBH | |
|---|---|---|
Market Cap | $31.76B | $18.55B |
Sector | Consumer Staples | Health |
52-Week High | $119.61 | $107.71 |
52-Week Low | $67.23 | $79.58 |
Enterprise Value | $37.93B | $25.61B |
Dividend Yield | 1.59% | 0.99% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Estée Lauder (EL) trades at $87.19, down 1.31% on the day, with a mixed technical picture showing bullish moving averages but neutral oscillators. The company faces fundamental challenges with a net loss of $1.13B in 2025 and negative profit margins, though recent quarters have consistently beaten EPS expectations. Analyst sentiment is divided with a Hold consensus and $91.67 price target, while institutional activity shows significant position changes including Bank of America's 950.9% stake increase in Q1 2026.
The stock presents a recovery opportunity with strong brand positioning and recent product launches like the Glimmer fragrance, but faces headwinds from declining revenues and profitability. Near-term catalysts include the upcoming Q2 2026 earnings report where EL is expected to post $0.3193 EPS. The key risk remains execution on margin improvement amid competitive pressures in the beauty sector.
ZBH trades at $97.78, up 1.27% today, with a bullish technical outlook supported by moving averages and recent earnings beats. The company reported Q2 2026 EPS of $2.07, exceeding expectations, and raised its 2026 outlook. Revenue growth remains steady at 4.8% year-over-year, though net income margin has moderated from 2023 peaks. Analyst consensus is a 'Buy' with a $103.56 price target, indicating modest upside potential from current levels.
The stock offers a balanced risk-reward profile with solid fundamentals and positive momentum, but faces headwinds from margin pressure and rising debt levels. Investors should weigh the strong institutional support and consistent earnings performance against competitive pressures and macroeconomic uncertainties affecting the medtech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Estee Lauder Companies Inc
Estee Lauder is the world leader in the global prestige beauty market, participating across skincare (56% of fiscal 2022 sales), makeup (26%), fragrance (14%), and haircare (4%) categories, with popular brands such as Estee Lauder, Clinique, MAC, La Mer, Jo Malone, Aveda, Bobbi Brown, Too Faced, Origins, Dr. Jart+, and The Ordinary. The firm operates in 150 countries, with 26% of fiscal 2022 revenue stemming from the Americas, 43% from Europe, the Middle East, and Africa, and 31% from Asia-Pacific. The company sells its products through department stores, travel retail, multi-brand specialty beauty stores, brand-dedicated freestanding stores, e-commerce, salons/spas, and perfumeries.
Read more on EL →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
